RYR2 and catecholaminergic polymorphic ventricular tachycardia: CPVT has a high mortality rate of up to 50% by the age of 30 years, but since β-blockers and/or implantable cardioverter-defibrillator (ICD) can at least partially prevent arrhythmias and sudden death, early diagnosis through clinical and genetic screening is essential for effective clinical management of patient's suffering from RYR-2 mediated arrhythmia [16].